Capital accelerating Gulf biotechnology
Explore the disclosed investments, funds, transactions and commitments supporting the region's biotechnology growth.
Where the money came from and went
Deals with a published figure are drawn here; every deal is listed in the table below.
Strategic deals tracked11Of 15 deals here, tracked by scope, partner and status
Data table
| Date | Investor and recipient | USD | Status | Market | Source |
|---|---|---|---|---|---|
| 8 July 2026 | Seha Investto Y-Innovations · PartnershipAnnounced partnership value. | $500m | Announced | Saudi ArabiaVaccines | Arab NewsVerified 22 September 2026 |
| May 2026 | Emkan Capital, Qatar Development Bank, Shorooq Partnersto Aumet · Equity | $12m | Closed | GCCOther biotechnology | Arab NewsSeries A · Verified 22 September 2026 |
| 14 January 2024 | PureHealthto Circle Health Group · Outbound acquisition | $1.2bn | Closed | UAEOther biotechnology | PureHealthAED 4.41bn at 2026-09-22 · Verified 22 September 2026 |
| 21 October 2024 | Lifera (Public Investment Fund)to SaudiBio with Novo Nordisk Saudi Arabia · Technology transfer and localisation agreement | Committed | Saudi ArabiaBiopharmaceuticals | LiferaVerified 22 September 2026 | |
| 27 October 2025 | Lifera (Public Investment Fund)to Jamjoom Pharma joint venture · Joint venture | Signed | Saudi ArabiaVaccines | LiferaVerified 22 September 2026 | |
| 30 October 2025 | Pfizer, Sanofi and MSDto Lifera · Memorandum of understanding | Announced | Saudi ArabiaVaccines | LiferaVerified 22 September 2026 | |
| 30 October 2025 | Lifera (Public Investment Fund)to King Faisal Specialist Hospital and Research Centre · Partnership | Signed | Saudi ArabiaCell and gene therapy | LiferaVerified 22 September 2026 | |
| November 2023 | Lifera (Public Investment Fund) and National Resilienceto Riyadh sterile injectables facility · Joint venture | Under construction | Saudi ArabiaBiopharmaceuticals | Contract PharmaVerified 22 September 2026 | |
| 24 June 2026 | Mubadala Bioto Biosidus licensing and supply agreement · Licensing and supply | Signed | UAEBiopharmaceuticals | ZawyaVerified 22 September 2026 | |
| 5 July 2025 | Department of Health Abu Dhabi, M42 and PureHealthto GEMMABio Therapeutics · Partnership | Proposed | UAECell and gene therapy | Department of Health - Abu DhabiVerified 22 September 2026 | |
| 24 June 2026 | Department of Health Abu Dhabi and M42to Mammoth Biosciences · Partnership | Announced | UAECell and gene therapy | Gulf NewsVerified 22 September 2026 | |
| 26 June 2026 | Abu Dhabi Biobankto BioTwin · Partnership | Signed | UAEDiagnostics | Gulf NewsVerified 22 September 2026 | |
| 24 June 2026 | MSDto Abu Dhabi logistics hub · Corporate investment | Announced | UAEOther biotechnology | World Pharma TodayVerified 22 September 2026 | |
| 12 June 2026 | Saudi Amaroxto CEL-SCI commercialisation agreement · Commercialisation and distribution agreement | Signed | Saudi ArabiaBiopharmaceuticals | Business WireVerified 22 September 2026 | |
| November 2025 | IB Venturesto Saudi biotechnology startups · Fund sizeFund size. | $50m | Available fund | Saudi ArabiaOther biotechnology | Nature Careers (news feature)Verified 22 September 2026 |
| 17 September 2026 | Riyadh summit participantsto Agreements announced at the summit · Aggregate of announced agreementsLower of two reported figures: Asharq Al-Awsat reports over SAR5bn and the organiser states SAR5.5bn. | $1.3bn | Announced | Saudi ArabiaOther biotechnology | Asharq Al-AwsatSAR 5bn at 2026-09-22 · Verified 22 September 2026 |
Capital Status Ledger
Each status is totalled on its own, keeping announced value and deployed capital distinct.
Each status is totalled separately: an announced partnership value and a closed equity round mark different stages of the same pipeline.
Data table
| Status | Total disclosed | Transactions | Median disclosed | Largest |
|---|---|---|---|---|
| Announced | $500m | 4 | $500m | $500m |
| Proposed | 1 | |||
| Signed | 5 | |||
| Committed | 1 | |||
| Closed | $1.2bn | 2 | $606m | $1.2bn |
| Available fund | $50m | 1 | $50m | $50m |
| Under construction | 1 |
GCC Biotechnology Investment Timeline
Each deal by quarter. Circle size shows the published figure; dashed circles mark deals with private terms.
Data table
| Quarter, and who invested | Transactions | Disclosed total | Private terms | Largest disclosed |
|---|---|---|---|---|
| Q4 2023Lifera (Public Investment Fund) and National Resilience | 1 | 1 | ||
| Q1 2024PureHealth | 1 | $1.2bn | $1.2bn | |
| Q4 2024Lifera (Public Investment Fund) | 1 | 1 | ||
| Q3 2025Department of Health Abu Dhabi, M42 and PureHealth | 1 | 1 | ||
| Q4 2025Lifera (Public Investment Fund), Pfizer, Sanofi and MSD, Lifera (Public Investment Fund), IB Ventures | 4 | $50m | 3 | $50m |
| Q2 2026Emkan Capital, Qatar Development Bank, Shorooq Partners, Mubadala Bio, Department of Health Abu Dhabi and M42, Abu Dhabi Biobank, MSD, Saudi Amarox | 6 | $12m | 5 | $12m |
| Q3 2026Seha Invest | 1 | $500m | $500m |
Context figures, held apart from capital
Market sizes, fund sizes, targets and forecasts that frame the deal flow above.
Data table
| Figure | Value | Kind | Market | Source |
|---|---|---|---|---|
| Targeted biotechnology contribution to Saudi non-oil GDPA government target for biotechnology's contribution to non-oil GDP by 2040, as reported by Arab News from the National Biotechnology Strategy. | $34.6bn | Economic-impact target | Saudi ArabiaBy 2040 | Arab NewsNational Biotechnology Strategy |
| Public Investment Fund assets under managementTotal fund assets across every sector, showing the scale of the balance sheet behind Lifera and the Kingdom's manufacturing programme. Sourced to the fund's own annual report. | $900bn+ | Sovereign assets under management | Saudi Arabia2025 | Public Investment FundPublic Investment Fund |
| Hevolution Foundation commitments to healthspan scienceCumulative over the 21 months to June 2024, as stated by the foundation, across a global grantee base. | $400m+ | Research funding commitment | Saudi Arabia21 months to June 2024 | Hevolution FoundationHevolution Foundation |
| XPRIZE Healthspan prize poolA prize pool, awarded on results. | $101m | Prize pool | Saudi ArabiaCompetition running to 2030 | Hevolution FoundationHevolution Foundation and XPRIZE |
| GCC pharmaceutical market, growing about 7.5% a yearAnnual market spending, from JLL research as reported by Khaleej Times. | $30bn+ | Market size | GCC2025 | Khaleej TimesJLL, reported by Khaleej Times |
| MENA venture funding across 688 deals, up 74% year on yearVenture funding across all sectors in MENA, the wider regional market around Gulf biotechnology. | $3.8bn | Venture funding total | MENAFY2025 | MAGNiTTMAGNiTT |
| Qatar package for biotechnology, artificial intelligence and future technologiesA combined allocation for biotechnology, artificial intelligence and other future technologies. | QAR 20bn | Government programme allocation | QatarAnnounced 2025 | ZawyaState of Qatar via Invest Qatar |
| Projected Qatari healthcare expenditure by 2030, from $6bn in 2024Healthcare spending forecast, more than doubling from 2024. | $13bn | Expenditure forecast | QatarBy 2030 | ZawyaInvest Qatar |
| Target annual capacity, Lifera and National Resilience sterile injectables facility, RiyadhTarget annual output, in units, for a facility under construction. | 125m+ units a year | Production capacity | Saudi ArabiaFacility under construction | Contract PharmaLifera and National Resilience |
| UAE nationals who took part in the Emirati Genome ProgrammeParticipation as described by the operator. The largest published analysis cohort from the programme is 43,608 individuals, in a September 2025 preprint. | 780,000 | Programme participation | UAECumulative, per the operator | M42M42 |
| Participants recruited across Qatar Biobank and Qatar Genome ProgrammeParticipants recruited across both programmes, as stated by the institute. | ~50,000 | Programme participation | QatarCumulative to 2026 | Qatar Precision Health InstituteQatar Precision Health Institute |